X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, WuXi ATU will serve as a cell processing manufacturing partner for the planned global clinical development of CABA-201, a 4-1BB-containing fully human CD19-CAR T, in systemic lupus erythematosus and idiopathic inflammatory myopathies, or myositis.
Lead Product(s): CABA-201
Therapeutic Area: Immunology Product Name: CABA-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cabaletta Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 22, 2023
Details:
Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.
Lead Product(s): INT-2104
Therapeutic Area: Oncology Product Name: INT-2104
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Interius BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Details:
PAS-004 (CIP-137401) is a small molecule allosteric inhibitor of MEK 1/2 in the Ras-Raf-MEK-ERK signaling pathway, which plays critical roles in the regulation of diverse cellular activities, including cell proliferation, survival, differentiation, and motility.
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: PAS-004
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Pasithea Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 18, 2023
Details:
Under this agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems.
Lead Product(s): Aav Vectors
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2022
Details:
TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.
Lead Product(s): TFC-1326
Therapeutic Area: Dermatology Product Name: TFC-1326
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sirona Biochem Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2022
Details:
Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Partner/Sponsor/Collaborator: Orbit Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022
Details:
Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.
Lead Product(s): AS1411
Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Qualigen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 05, 2020
Details:
Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.
Lead Product(s): ST-067
Therapeutic Area: Oncology Product Name: ST-067
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Simcha Therapeutics
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
